Dulaglutide vs Semaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicDulaglutideSemaglutide
What it is

A GLP-1 receptor agonist. The label states that dulaglutide has 90% amino acid sequence similarity to human GLP-1.1

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.3

FDA status

FDA-approved

FDA-approved as Trulicity1,2

FDA-approved. Drugs@FDA lists Trulicity with an original approval date of September 18, 2014. The label carries a boxed warning about thyroid C-cell tumors in rats.1,2

Is dulaglutide FDA-approved?

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy3,4,5,6

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.3,4,5,6

Is semaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.7

Not among the six peptides the policy lists.7

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial REWIND (NCT01394952): a randomized, double-blind, placebo-controlled cardiovascular outcomes trial in 9,901 adults with type 2 diabetes and established cardiovascular disease or multiple risk factors, with a median follow-up of 5.4 years.1
  • Large randomized human trial A 26-week randomized, double-blind trial in 807 adults with type 2 diabetes that compared dulaglutide with metformin, one of several blood-sugar trials in the label.1
  • Controlled human trial A 26-week randomized, double-blind, placebo-controlled trial (NCT02963766) in 154 children aged 10 and older with type 2 diabetes.1

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.3
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.3
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.3
Records collected

11 ClinicalTrials.gov records and 38 PubMed records collected

140 ClinicalTrials.gov records and 108 PubMed records collected

Area of study

Metabolic and weight, Heart and blood vessels1

Metabolic and weight, Heart and blood vessels, Liver3

Latest dated events
  1. DailyMed publishes the Trulicity label version cited on this page.1
  2. FDA approves Trulicity, according to Drugs@FDA.2
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.8
  2. DailyMed publishes the Wegovy label version cited on this page.3
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.9

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  2. 2
    Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  4. 4
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  9. 9
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026